4.3 Review

Cerebrospinal fluid biomarkers in Creutzfeldt-Jakob disease

期刊

CLINICAL NEUROLOGY AND NEUROSURGERY
卷 107, 期 5, 页码 355-360

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.clineuro.2004.12.002

关键词

prion disease; 14-3-3 protein; tau protein; amyloid-beta; variant CJD; sporadic CJD; differential diagnosis

向作者/读者索取更多资源

Creutzfeldt-Jakob disease (CJD) is a rare neurodegenerative disorder. Since the emergence of variant CID (vCJD) vigilance concerning the disease's incidence has increased and the interest in accurate in vivo diagnosis has augmented. So far, a large number of biomarkers has been investigated as aid in the differential diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD) and vCJD. These include, among others, neuron-specific enolase (NSE), microtubuli associated protein Tau, S-100 beta, amyloid-beta (A beta(1-42)) and the 14-3-3 protein. Multiple studies have confirmed that CSF detection of 14-3-3 protein by Western blot was the best single biomarker for sCJD with an average sensitivity and specificity of 92%. Also, in genetic and iatrogenic CJD (iCJD) patients with an average disease duration of less than 1 year, 14-3-3 is the best differential biomarker. Unfortunately, the 14-3-3 protein has a lower sensitivity if the disease duration exceeds beyond I year in both sporadic CID and other CJD types (vCJD, and specific genetic or iatrogenic CJD types). (c) 2004 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据